Imipenem versus moxalactam in the treatment of serious infections.

Imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) was compared to moxalactam in a randomized therapeutic trial involving 39 evaluable patients with serious bacterial infections. Of those treated with imipenem, 89% were cured or improved versus 60% for moxalactam (P = 0.06). Althoug...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Eron, L J, Hixon, D L, Park, C H, Goldenberg, R I, Poretz, D M
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1983
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC185393/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6581755/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.24.6.841
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!